JP2006510654A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510654A5
JP2006510654A5 JP2004558236A JP2004558236A JP2006510654A5 JP 2006510654 A5 JP2006510654 A5 JP 2006510654A5 JP 2004558236 A JP2004558236 A JP 2004558236A JP 2004558236 A JP2004558236 A JP 2004558236A JP 2006510654 A5 JP2006510654 A5 JP 2006510654A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation according
kinase inhibitor
patient
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004558236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040140 external-priority patent/WO2004053107A2/en
Publication of JP2006510654A publication Critical patent/JP2006510654A/ja
Publication of JP2006510654A5 publication Critical patent/JP2006510654A5/ja
Pending legal-status Critical Current

Links

JP2004558236A 2002-12-06 2003-12-05 糖尿病を処置する方法 Pending JP2006510654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43124102P 2002-12-06 2002-12-06
PCT/US2003/040140 WO2004053107A2 (en) 2002-12-06 2003-12-05 Methods for treating diabetes

Publications (2)

Publication Number Publication Date
JP2006510654A JP2006510654A (ja) 2006-03-30
JP2006510654A5 true JP2006510654A5 (https=) 2007-02-01

Family

ID=32507688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004558236A Pending JP2006510654A (ja) 2002-12-06 2003-12-05 糖尿病を処置する方法

Country Status (6)

Country Link
US (1) US20040171659A1 (https=)
EP (1) EP1583535A4 (https=)
JP (1) JP2006510654A (https=)
AU (1) AU2003299652A1 (https=)
CA (1) CA2511763A1 (https=)
WO (1) WO2004053107A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7765004B2 (en) * 2005-04-28 2010-07-27 Cardiac Pacemakers, Inc. Methods and systems for managing fusion and noise in cardiac pacing response classification
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
CA2857374A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4619652A (en) * 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6096748A (en) * 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
ES2221213T3 (es) * 1997-10-20 2004-12-16 F. Hoffmann-La Roche Ag Inhibidores de kinasa biciclicos.
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体

Similar Documents

Publication Publication Date Title
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
JP2003520232A5 (https=)
JP2005237328A5 (https=)
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
JP2010502564A (ja) 眼科用経皮吸収型製剤
DE602004013993D1 (de) R für biologische wirksubstanz zur oralen verabreichung
CA2518219A1 (en) Igf-binding protein-derived peptide or small molecule
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
JP2005526024A5 (https=)
PT1401413E (pt) Uso de inibidores da tirosina cinase para tratar doenças alérgicas
JP2009541387A5 (https=)
RU2006118786A (ru) Твердый препарат
JP2006510654A5 (https=)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
CA2604640A1 (en) Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
WO2007092086A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
CA2608163A1 (en) Hydralazine compositions and methods
JP2007504268A5 (https=)
SE0002729D0 (sv) Novel compound form
EP1393738A4 (en) MEDICINE AGAINST DIABETES
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
CA2504873A1 (en) Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
KR20170124322A (ko) 알러지 질환 치료제 전달을 위한 용해성 미세바늘 패치
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания